# OnCo record fulzerasib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/fulzerasib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "fulzerasib" ;
  schema:name "Fulzerasib"@en ;
  schema:description "Fulzerasib was the first KRAS G12C-blocking pill approved in China, for lung cancers carrying that mutation after earlier treatment."@en ;
  schema:url <https://onco.cc/drugs/fulzerasib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.genfleet.com/en/>, <https://doi.org/10.1016/j.jtho.2024.08.005>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule covalent KRAS G12C inhibitor" ;
  schema:alternateName "Dupert" ;
  onco:approval "China 2024: KRAS G12C-mutant advanced NSCLC after at least one systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:companies <https://onco.cc/companies/genfleet/>, <https://onco.cc/companies/innovent/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/> ;
  onco:trials <https://onco.cc/trials/nct07601048/>, <https://onco.cc/trials/nct07581912/>, <https://onco.cc/trials/nct06936644/> ;
  onco:people <https://onco.cc/people/yu-michael/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-zhou-j-thorac-oncol/> .